SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-21-015265
Filing Date
2021-11-09
Accepted
2021-11-09 16:01:41
Documents
14
Period of Report
2021-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nbrv-20211109x8k.htm   iXBRL 8-K 36757
2 EX-99.1 nbrv-20211109xex99d1.htm EX-99.1 262680
3 GRAPHIC nbrv-20211109xex99d1001.jpg GRAPHIC 5092
  Complete submission text file 0001558370-21-015265.txt   445399

Data Files

Seq Description Document Type Size
4 EX-101.SCH nbrv-20211109.xsd EX-101.SCH 3151
5 EX-101.LAB nbrv-20211109_lab.xml EX-101.LAB 15883
6 EX-101.PRE nbrv-20211109_pre.xml EX-101.PRE 10214
7 EXTRACTED XBRL INSTANCE DOCUMENT nbrv-20211109x8k_htm.xml XML 4848
Mailing Address 414 COMMERCE DRIVE STE 120 FORT WASHINGTON PA 19034
Business Address 25-28 NORTH WALL QUAY DUBLIN L2 D01 H104 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 211391941
SIC: 2834 Pharmaceutical Preparations